UTHR Tingkat bathi reged United Therapeutics Corp.

Lambang korporat lan logo United Therapeutics Corp. (UTHR)

United Therapeutics holds the status of a lifesaver in the treatment of rare lung pathologies, enjoying the absolute trust of physicians. The gross profit margin demonstrates the efficiency of this model, where 86.30 determines the current status of the parameter. Growth is driven by the dominance of Tyvaso and a breakthrough in xenotransplantation, although stability requires the monitoring of patent protection while maintaining a safe financial balance.

United Therapeutics (UTHR): Margin reged saka 04.07.2022 nganti 20.11.2026

Rincian analitis lan laporan data perusahaan United Therapeutics Corporation (UTHR)

- nilai pasar lan prakiraan target analis:
Produk asil prodhuksi unither.com

Gross margin measures the portion of revenue remaining after covering direct production costs, determining the fundamental efficiency of the business model. For United Therapeutics (UTHR), this metric reflects the company's ability to pass the costs of complex cold-chain logistics for life-saving drugs onto the end consumer. Analyzing gross profit margins allows for the rapid identification of rising costs of goods sold or a decline in pricing power. Consistently high values confirm high added value and the financial stability of the asset.